Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Nkarta stock price, quote, forecast and news

NKTX
US65487U1088
A2P797

Price

6.42
Today +/-
-0.08
Today %
-1.39 %
P

Nkarta stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Nkarta stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Nkarta stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Nkarta stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Nkarta's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Nkarta Stock Price History

DateNkarta Price
9/11/20246.42 undefined
9/10/20246.51 undefined
9/9/20245.91 undefined
9/6/20245.32 undefined
9/5/20245.43 undefined
9/4/20245.39 undefined
9/3/20245.15 undefined
8/30/20245.31 undefined
8/29/20245.50 undefined
8/28/20245.24 undefined
8/27/20245.38 undefined
8/26/20245.66 undefined
8/23/20245.32 undefined
8/22/20245.15 undefined
8/21/20245.38 undefined
8/20/20245.11 undefined
8/19/20245.21 undefined
8/16/20245.07 undefined
8/15/20245.01 undefined

Nkarta Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Nkarta, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Nkarta from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Nkarta’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Nkarta. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Nkarta’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Nkarta’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Nkarta’s growth potential.

Nkarta Revenue, EBIT and net profit per share

DateNkarta RevenueNkarta EBITNkarta Net Income
2029e257.27 M undefined0 undefined-109.04 M undefined
2028e136.35 M undefined-158.54 M undefined-147.18 M undefined
2027e61.06 M undefined-213.08 M undefined-188.2 M undefined
2026e2.3 M undefined-202.39 M undefined-154.26 M undefined
2025e0 undefined-156.15 M undefined-123.43 M undefined
2024e0 undefined-135.92 M undefined-117.79 M undefined
20230 undefined-131.65 M undefined-117.5 M undefined
20220 undefined-118.96 M undefined-113.84 M undefined
20210 undefined-86.43 M undefined-86.08 M undefined
20200 undefined-51.51 M undefined-91.36 M undefined
2019120,000 undefined-22.35 M undefined-21.08 M undefined
20186.55 M undefined-360,000 undefined-270,000 undefined

Nkarta Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
2018201920202021202220232024e2025e2026e2027e2028e2029e
60000000261136257
---------2,950.00122.9588.97
------------
000000000000
0-22-51-86-118-131-135-156-202-213-1580
---------10,100.00-349.18-116.18-
0-21-91-86-113-117-117-123-154-188-147-109
--333.33-5.4931.403.54-5.1325.2022.08-21.81-25.85
30.4330.4332.6332.8643.6349.01000000
------------
Details

Keystats

ⓘ

Revenue and Growth

The Nkarta Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Nkarta is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (k)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
201820192020202120222023
           
7.937314.9238.1352.1248.19
000000
000000
000000
0.20.53.97.78.54.88
8.137.5318.8245.8360.6253.07
1.310.217.924.5107.7119.28
000000
000000
000000
000000
0.10.713.64.66.54
1.410.918.928.1112.3125.81
9.548.4337.7273.9472.9378.89
           
12.759.80000.01
0.21.2439.2455.2690.8708.71
-5.6-26.7-118-204.1-317.9-435.43
000000
000-200-7008
7.334.3321.2250.9372.2273.28
0.41.91.21.11.83.67
1.64.26.710.319.418.81
0.12.10.91.50.90.86
000000
000000
2.18.28.812.922.123.33
000000
000000
0.25.97.61078.782.27
0.25.97.61078.782.27
2.314.116.422.9100.8105.6
9.648.4337.6273.8473378.89
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Nkarta provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Nkarta's financial health and stability.

Assets

Nkarta's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Nkarta must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Nkarta after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Nkarta's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
201820192020202120222023
0-21-91-86-113-117
000125
000000
-520-13310
0154323731
000000
000000
-5-18-43-67-57-86
0-1-7-5-47-28
0-18-21032-18479
0-16-20237-137107
000000
050000
04332912190
04932912190
------
000000
-51276-34-22-6
-5.94-20.3-51.02-72.96-104.11-114.31
000000

Nkarta stock margins

The Nkarta margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Nkarta. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Nkarta.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Nkarta's sales revenue. A higher gross margin percentage indicates that the Nkarta retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Nkarta's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Nkarta's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Nkarta's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Nkarta. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Nkarta's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Nkarta Margin History

Nkarta Gross marginNkarta Profit marginNkarta EBIT marginNkarta Profit margin
2029e0 %0 %-42.38 %
2028e0 %-116.27 %-107.94 %
2027e0 %-348.98 %-308.24 %
2026e0 %-8,818.53 %-6,721.48 %
2025e0 %0 %0 %
2024e0 %0 %0 %
20230 %0 %0 %
20220 %0 %0 %
20210 %0 %0 %
20200 %0 %0 %
20190 %-18,625 %-17,566.67 %
20180 %-5.5 %-4.12 %

Nkarta Stock Sales Revenue, EBIT, Earnings per Share

The Nkarta earnings per share therefore indicates how much revenue Nkarta has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Nkarta earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Nkarta's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Nkarta’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Nkarta's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Nkarta Revenue, EBIT and net profit per share

DateNkarta Sales per ShareNkarta EBIT per shareNkarta Earnings per Share
2029e3.65 undefined0 undefined-1.55 undefined
2028e1.93 undefined0 undefined-2.09 undefined
2027e0.87 undefined0 undefined-2.67 undefined
2026e0.03 undefined0 undefined-2.19 undefined
2025e0 undefined0 undefined-1.75 undefined
2024e0 undefined0 undefined-1.67 undefined
20230 undefined-2.69 undefined-2.4 undefined
20220 undefined-2.73 undefined-2.61 undefined
20210 undefined-2.63 undefined-2.62 undefined
20200 undefined-1.58 undefined-2.8 undefined
20190 undefined-0.73 undefined-0.69 undefined
20180.22 undefined-0.01 undefined-0.01 undefined

Nkarta business model

Nkarta Inc is a biopharmaceutical company based in South San Francisco, California. The company was founded in 2015 by Dr. Raphael Rousseau (CEO) to develop a groundbreaking new therapy for cancer patients. The business model of Nkarta is based on the development of novel CAR-T cell therapies. These are a special type of immunotherapy in which the patient's own immune cells are genetically modified and used to target tumor cells. Unlike conventional chemotherapy or radiation, which can also attack healthy cells, CAR-T cell therapies specifically target cancer cells while sparing the surrounding healthy tissue. Nkarta is divided into various business areas, including research and development of new therapies, manufacturing and production of CAR-T cells, and clinical trials and approval processes for broad application. One of Nkarta's key products is NKR-2, a CAR-T cell therapy based on natural killer cells. These cells have high activity against cancer cells and can respond quickly to threats. NKR-2 differentiates itself from other therapies by its ability to be effective even at low concentrations. This means that fewer cells are needed and the risk of unwanted side effects is reduced. Nkarta is also working on other projects, including NKX101, which specializes in treating solid tumors, and Voretigene Neparvovec, a gene therapy for the rare hereditary retinal disease. In 2020, Nkarta entered into a partnership with CRISPR Therapeutics to explore the joint potential of CRISPR gene editing and CAR-T cell therapy. The collaboration aims to improve the precision and effectiveness of CAR-T cell therapies and ultimately increase the chances of a cure for cancer patients. Overall, Nkarta has had an impressive success story in recent years. The company has raised several million dollars in funding and continues to expand. The groundbreaking technology of CAR-T cell therapies is promising and has the potential to have a sustainable impact on healthcare. With Nkarta at the forefront, the future could look much more hopeful for cancer patients. Nkarta is one of the most popular companies on Eulerpool.com.

Nkarta SWOT Analysis

Strengths

Nkarta Inc has several strengths that contribute to its competitive advantage in the market. These strengths include:

  • Strong Research and Development: Nkarta Inc invests significantly in research and development, allowing them to develop innovative and cutting-edge therapies.
  • Diverse Product Portfolio: The company has a diverse product portfolio, catering to different medical needs and target populations.
  • Talented Workforce: Nkarta Inc boasts a highly skilled and experienced workforce, including scientists, researchers, and executives, enabling them to drive innovation and execute strategic plans effectively.
  • Strong Intellectual Property: The company holds strong intellectual property rights, providing a competitive edge and protecting their innovations from competitors.
  • Strategic Partnerships: Nkarta Inc has established strategic partnerships with key industry players, allowing them access to additional resources, expertise, and market reach.

Weaknesses

Despite its strengths, Nkarta Inc also faces certain weaknesses that pose challenges to its growth and success. These weaknesses include:

  • Dependence on Funding: Like many biotech companies, Nkarta Inc relies heavily on funding sources such as venture capital and public financing, making their financial stability sensitive to market fluctuations.
  • Limited Market Reach: Nkarta Inc primarily operates within a niche market, which may limit their potential customer base and revenue streams.
  • Regulatory Challenges: The biotech industry is subject to rigorous regulations and approvals, which can result in delays or barriers to market entry for Nkarta's products.

Opportunities

Nkarta Inc can capitalize on various opportunities to enhance its market position and growth prospects. These opportunities include:

  • Expanding Target Market: Nkarta Inc can explore opportunities to expand its target market by identifying new therapeutic areas or developing partnerships in different regions.
  • Emerging Technologies: The advancements in technologies such as gene editing and cell therapies present new avenues for Nkarta Inc to develop innovative products.
  • Increasing Demand for Immunotherapies: The growing demand for immunotherapies represents a significant opportunity for Nkarta Inc to leverage its expertise in cellular therapies.

Threats

Nkarta Inc faces a range of threats that could impact its future growth and market position. These threats include:

  • Competition: The biotech industry is highly competitive, with the presence of both established players and emerging startups that may pose a threat to Nkarta's market share.
  • Regulatory Hurdles: Changes in regulations or difficulties in obtaining necessary approvals and licenses can pose challenges to Nkarta Inc's product development and commercialization plans.
  • Cost of Research and Development: The high cost of research and development, clinical trials, and manufacturing processes can strain Nkarta Inc's financial resources.

Nkarta Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Nkarta historical P/E ratio, EBIT, and P/S ratio.

Nkarta shares outstanding

The number of shares was Nkarta in 2023 — This indicates how many shares 49.014 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Nkarta earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Nkarta's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Nkarta’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Nkarta's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for Nkarta.

Nkarta latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2024-0.46 -0.34  (25.93 %)2024 Q2
3/31/2024-0.57 -0.58  (-1.81 %)2024 Q1
12/31/2023-0.6 -0.57  (5.49 %)2023 Q4
9/30/2023-0.69 -0.52  (24.33 %)2023 Q3
6/30/2023-0.69 -0.6  (13.49 %)2023 Q2
3/31/2023-0.71 -0.63  (11.26 %)2023 Q1
12/31/2022-0.65 -0.67  (-3.28 %)2022 Q4
9/30/2022-0.63 -0.58  (7.61 %)2022 Q3
6/30/2022-0.6 -0.61  (-1.36 %)2022 Q2
3/31/2022-0.73 -0.79  (-7.76 %)2022 Q1
1
2

Eulerpool ESG Scorecard© for the Nkarta stock

Eulerpool World ESG Rating (EESG©)

54/ 100

🌱 Environment

55

👫 Social

74

🏛️ Governance

32

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees52
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept❌
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting❌
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Nkarta list of shareholders

%
Name
Stocks
Change
Date
6.24624 % Boxer Capital, L.L.C.4,407,3502,967,3501/8/2024
5.34019 % Samsara BioCapital, LLC3,768,035900,0003/29/2024
5.05780 % New Enterprise Associates (NEA)3,568,78103/27/2024
4.88946 % Adage Capital Management, L.P.3,450,000-250,00012/31/2023
4.81859 % Deerfield Management Company, L.P.3,400,000012/31/2023
4.48049 % GSK plc3,161,4323,161,4323/27/2024
4.02004 % EQT Life Sciences2,836,5392,836,5392/8/2024
3.86905 % Commodore Capital LP2,730,000012/31/2023
3.13065 % BlackRock Institutional Trust Company, N.A.2,208,990-193,83512/31/2023
2.21162 % The Vanguard Group, Inc.1,560,51861,77812/31/2023
1
2
3
4
5
...
10

Nkarta Executives and Management Board

Mr. Paul Hastings63
Nkarta President, Chief Executive Officer, Director (since 2018)
Compensation 4.74 M
Dr. Alicia Hager53
Nkarta Corporate Secretary, Chief Legal Officer
Compensation 2.06 M
Ms. Angela Thedinga41
Nkarta Independent Director
Compensation 302,473
Dr. Ali Behbahani47
Nkarta Independent Chairman of the Board
Compensation 243,990
Ms. Leone Patterson60
Nkarta Independent Director
Compensation 213,490
1
2
3

Most common questions regarding Nkarta

What values and corporate philosophy does Nkarta represent?

Nkarta Inc represents a strong set of values and corporate philosophy. As a biotechnology company, Nkarta Inc is committed to transforming the lives of patients with complex diseases by harnessing the power of natural killer (NK) cells. The company believes in scientific innovation and collaboration to develop groundbreaking therapies. Nkarta Inc is devoted to delivering effective and safe treatments while maintaining the highest ethical standards. With a passion for improving patient outcomes, Nkarta Inc strives to be a leader in the biotech industry by driving advancements in cell therapy.

In which countries and regions is Nkarta primarily present?

Nkarta Inc is primarily present in the United States.

What significant milestones has the company Nkarta achieved?

Nkarta Inc, a leading biotechnology company, has achieved several significant milestones. Firstly, they successfully completed their IPO in 2020, raising substantial capital to fund their ongoing research and development efforts. Additionally, Nkarta has made remarkable progress in advancing their pipeline of novel natural killer (NK) cell therapies. They have received clearance from the FDA for their Investigational New Drug (IND) application, allowing them to initiate clinical trials. Nkarta has also forged strategic collaborations with renowned institutions, further reinforcing their expertise and expanding their reach in the field of cell therapies. These milestones demonstrate Nkarta Inc's commitment to revolutionizing cancer treatment through innovative therapies harnessing the power of NK cells.

What is the history and background of the company Nkarta?

Nkarta Inc, a biotechnology company founded in 2015, focuses on developing cellular therapies for cancer treatment. With headquarters in South San Francisco, California, Nkarta operates with a vision to harness the power of the body's immune system to combat cancer effectively. The company specializes in natural killer (NK) cells, which play a crucial role in protecting against tumor growth. Leveraging their proprietary technology, Nkarta engineers enhanced NK cells, known as NKT cells, to enhance their potency and persistence. As a prominent player in the field of cellular immunotherapy, Nkarta Inc strives to advance innovative treatments and improve outcomes for patients battling various cancers.

Who are the main competitors of Nkarta in the market?

The main competitors of Nkarta Inc in the market are Adaptimmune Therapeutics, bluebird bio, and Celgene Corporation.

In which industries is Nkarta primarily active?

Nkarta Inc is primarily active in the biotechnology industry.

What is the business model of Nkarta?

Nkarta Inc is a biotechnology company specializing in the development of cell therapies to treat cancer. The company's business model revolves around advancing its proprietary natural killer (NK) cell therapies. Nkarta Inc focuses on developing and commercializing off-the-shelf treatments that harness the power of the body's immune system to eliminate tumors. By genetically engineering and enhancing NK cells to target and kill cancer cells, Nkarta Inc aims to provide effective and accessible treatments for patients. As a leading player in the field of cell therapy, Nkarta Inc is committed to revolutionizing cancer treatment through its innovative business model.

What is the P/E ratio of Nkarta 2024?

The Nkarta P/E ratio is -2.67.

What is the P/S ratio of Nkarta 2024?

The Nkarta P/S ratio is 0.

What is the AlleAktien quality score of Nkarta?

The AlleAktien quality score for Nkarta is 2/10.

What is the revenue of Nkarta 2024?

The revenue cannot currently be calculated for Nkarta.

How high is the profit of Nkarta 2024?

The expected Nkarta profit is -117.79 M USD.

What is the business model of Nkarta

Nkarta Inc is a biotechnology company specializing in developing innovative and personalized therapies for cancer patients based on natural killer cells (NK cells). The company has a business model that spans multiple sectors and offers a wide range of products and services. The first sector of Nkarta is the research and development of personalized NK cell therapies for cancer patients. NK cells are part of the innate immune system and can directly attack and kill cancer cells. Nkarta utilizes advanced technologies such as CRISPR/Cas9 genome editing and CAR (chimeric antigen receptor)-based NK cell therapies to enhance the effectiveness of NK cells. The company is working on developing therapies for various types of cancer, including leukemia, lymphoma, and solid tumors. The second sector of Nkarta is the manufacturing and provision of NK cell products for clinical studies. Nkarta has its own production facility that is GMP certified and meets the highest quality standards. The company offers customers a wide range of products such as natural killer cells (NK cells) obtained from the patient's blood or donor blood, CAR NK cells, as well as specialized devices and consumables. The third sector of Nkarta is collaboration with other companies and institutions in the development of personalized NK cell therapies. Nkarta works with various partners to accelerate the development of NK cell therapies and improve the effectiveness of NK cells in cancer therapy. The company recently partnered with CRISPR Therapeutics to further develop its CAR NK cell technology and conduct clinical studies. In addition to these sectors, Nkarta is also active in the field of financing. The company has conducted several funding rounds, raising over $100 million. These funds are used to finance research and development, manufacturing of NK cell products, and expansion of business operations. In summary, Nkarta offers a wide range of products and services in the field of personalized NK cell therapy. The company has a comprehensive business model that spans multiple sectors, including research and development, manufacturing of NK cell products, collaboration with partners, and financing. Thanks to its innovative technologies and highly skilled employees, Nkarta is well-positioned to offer its customers effective and personalized cancer treatment.

What is the Nkarta dividend?

Nkarta pays a dividend of 0 USD distributed over payouts per year.

How often does Nkarta pay dividends?

The dividend cannot currently be calculated for Nkarta or the company does not pay out a dividend.

What is the Nkarta ISIN?

The ISIN of Nkarta is US65487U1088.

What is the Nkarta WKN?

The WKN of Nkarta is A2P797.

What is the Nkarta ticker?

The ticker of Nkarta is NKTX.

How much dividend does Nkarta pay?

Over the past 12 months, Nkarta paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Nkarta is expected to pay a dividend of 0 USD.

What is the dividend yield of Nkarta?

The current dividend yield of Nkarta is .

When does Nkarta pay dividends?

Nkarta pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Nkarta?

Nkarta paid dividends every year for the past 0 years.

What is the dividend of Nkarta?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Nkarta located?

Nkarta is assigned to the 'Health' sector.

Wann musste ich die Aktien von Nkarta kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Nkarta from 9/13/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/13/2024.

When did Nkarta pay the last dividend?

The last dividend was paid out on 9/13/2024.

What was the dividend of Nkarta in the year 2023?

In the year 2023, Nkarta distributed 0 USD as dividends.

In which currency does Nkarta pay out the dividend?

The dividends of Nkarta are distributed in USD.

All fundamentals about Nkarta

Our stock analysis for Nkarta Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Nkarta Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.